Aerovate Therapeutics, Inc.
AVTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2,651 | $20,855 | $25,096 | $10,073 |
| - Cash | $34 | $23 | $22 | $54 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $2,618 | $20,833 | $25,075 | $10,019 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$74 | -$81 | -$53 | -$23 |
| % Margin | – | – | – | – |
| Net Income | -$70 | -$76 | -$52 | -$23 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.44 | -2.87 | -2.1 | -1.87 |
| % Growth | 15% | -36.7% | -12.3% | – |
| Operating Cash Flow | -$71 | -$57 | -$39 | -$27 |
| Capital Expenditures | $0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$71 | -$57 | -$39 | -$28 |